Terms: = Ovarian cancer AND ERCC3, RAD25, 2071, ENSG00000163161, GTF2H, TFIIH, BTF2, P19447, XPB AND Treatment
5 results:
1. Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.
Kong S; Sun J; Sui X; Zhang S; Qi Y; Ma Y; Li S
Acta Obstet Gynecol Scand; 2023 Jul; 102(7):935-941. PubMed ID: 37059424
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy.
Billingsley CC; Jacobson SN; Crafton SM; Crim AK; Li Q; Hade EM; Cohn DE; Fowler JM; Copeland LJ; Salani R; Backes FJ; O'Malley DM
Int J Gynecol Cancer; 2015 Sep; 25(7):1331-6. PubMed ID: 26067861
[TBL] [Abstract] [Full Text] [Related]
3. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK; Guo Y; Miller MR; Yu JJ
Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
[TBL] [Abstract] [Full Text] [Related]
4. Molecular characterisation of a panel of human ovarian carcinoma xenografts.
Codegoni AM; Nicoletti MI; Buraggi G; Valoti G; Giavazzi R; D'Incalci M; Landoni F; Maneo A; Broggini M
Eur J Cancer; 1998 Aug; 34(9):1432-8. PubMed ID: 9849428
[TBL] [Abstract] [Full Text] [Related]
5. [Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].
Senn HJ; Lei D; Castaño-Almendral A; Brunner KW; Martz G; Obrecht P; Melchert F; Rhomberg W
Schweiz Med Wochenschr; 1980 Aug; 110(33):1202-8. PubMed ID: 7423163
[TBL] [Abstract] [Full Text] [Related]
